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Introduction 
Atrial fibrillation (AF) is a major cause of stroke and mortality, and optimal stroke risk stratification is 
essential to reduce the burden of stroke among AF patients.
1
 The increase in AF prevalence has 
correspondingly increased the proportion of AF patients that should be considered for antithrombotic 
treatment. Preventing stroke with oral anticoagulant treatment (OAC) comes at the cost of an increased 
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bleeding risk, but the net clinical benefit of treatment is often substantially higher than withholding 
treatment.
2
  
Risk stratification helps identify those AF patients who may or may not need thromboprophylaxis.
3
 In 
general, the default should be the provision of stroke prevention by means of oral anticoagulation 
unless patients are low risk.
4
 However, ‘low risk’ categorization is often arbitrary and has been subject 
for much debate. A source for this debate originates from the interpretation of estimated stroke risk on 
the basis of the risk factors, which are included in stroke risk stratification tools.
5,6
 Here we briefly 
review the current AF guidelines recommendations on OAC treatment. Specific focus is given to the 
importance of concise interpretation of female sex as a risk factor for stroke in AF. 
 
Guideline discrepancies 
Contemporary European and North American AF guidelines recommend the use of CHA2DS2-VASc 
(Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke/transient 
ischemic attack, Vascular disease, Age 65-74 years, Sex category) score.
3,7
 The maximum cumulative 
score is 9, where female sex contributes one point to reflect the overall increased risk of stroke among 
female AF patients. However, the threshold for recommendations are not aligned, where different 
recommendations of antithrombotic therapy varies across different risk categories, see Table 1. 
Currently, North American guidelines for managing AF patients suggest that patients with a CHA2DS2-
VASc score of 1 may be considered for no antithrombotic therapy, aspirin, or oral anticoagulant.
7
 In an 
observational cohort study including 49916 AF patients with a CHA2DS2-VASc score of 1 beyond sex, 
treatment with warfarin in comparison with no treatment or aspirin exhibited a positive net clinical 
benefit.
2
 These data supported the 2012 European Society of Cardiology
8
 (ESC) guidelines to 
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recommend OAC treatment, and also showed that aspirin should not be considered as an effective 
stroke prevention strategy in these patients. However, the North American guidelines do not separate 
the risk factor of sex from other (clinical) stroke risk factors. Thus, female patients with no additional 
stroke risk factors may even be considered for antithrombotic therapy based on these recommendations. 
To our knowledge, there has not been evidence published to support the use of aspirin treatment to 
prevent stroke in female patients with AF with no additional stroke risk factors. 
In Europe, the guideline recommendations differentiate between males and females by setting different 
point level thresholds for recommending OAC treatment initiation. In the contemporary ESC AF 
guidelines, the treating physician is required to make a choice based on the CHA2DS2-VASc score 
points and an individualized stroke risk assessment.
3
 Specifically, for male patients with a single non-
sex specific stroke risk factor, i.e. 1 point and females with 2 points, the guideline suggest to ‘consider’ 
OAC treatment initiation. For two or more non-sex specific CHA2DS2-VASc score risk factors, i.e. 
male patients with ≥2 points and females with ≥3 points, there is a clear recommendation of OAC 
treatment (Table 1).  
Withholding OAC treatment initiating in patients with a score of 2 (i.e. two risk factor components for 
males, and one risk factor for females) was investigated in a large cohort of AF patients who did not 
receive antithrombotic treatment.
9
 The rate of thromboembolism per 100 person-years was 1.97 – for 
most clinicians, clearly high enough to warrant stroke prevention. Nevertheless, the approach of 
recommending treatment based on rates from cumulative score by including sex as a risk factor may be 
too simplistic. 
 
Stroke risk in female AF patients 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Madsen and colleagues recently provided an update on the impact of conventional stroke risk factors 
on the occurrence of stroke in female individuals compared with males.
10
 They accurately highlighted 
the consistently reported higher crude risk of ischemic stroke among female AF patients compared with 
males. However, significant interactions between female sex and age or other stroke risk factors have 
been repeatedly reported.  
Indeed, in terms of stroke risk stratification, including female sex (the “Sc” component) as an 
independent stroke risk factor in AF may be too simplistic to appreciate the higher stroke risk observed 
among female AF patients, which has a dependency on age and other risk factors. In a recent analysis 
including nearly 240,000 newly diagnosed AF patients (48.7% females), we investigated the “Sc” 
component as a prognostic factor rather than a risk factor for stroke within the CHA2DS2-VASc 
score.
11
 This investigation indicated that the excess female sex-related risk of stroke was evident only 
in the presence of other CHA2DS2-VASc risk factors, especially among female AF patients with ≥2 
concomitant non-gender CHA2DS2-VASc risk factors. Indeed, when including female sex as an 
interaction term (and not an independent risk factor), we observed a 5-year risk ratio of stroke between 
1.16 (95%CI, 1.02 – 1.30) and 1.43 (95%CI, 1.30 – 1.56), dependent on the number of concomitant 
sex-specific CHA2DS2-VASc risk factors.  
These results highlighted that female sex could be considered a risk modifier rather than an 
independent risk factor for stroke among AF patients
.
 Hence, female AF patients without other 
CHA2DS2-VASc risk factors could be considered to be stratified into a ‘low stroke risk’ category, and 
thus potentially requiring no antithrombotic therapy. This would entail that the initial step in stroke risk 
stratification is the identification of low risk patients (CHA2DS2-VASc 0 in males, 1 in females) who 
do not need any antithrombotic therapy, following which stroke prevention (i.e. oral anticoagulation) 
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should be offered to those with ≥1 stroke risk factors.4 This has also been acknowledged in the recent 
European Heart Rhythm Association Consensus Document on sex differences in cardiac arrhythmias
14
, 
which emphasized a consistent underrepresentation of female patients in AF trials and recommended 
consideration of OAC use in all female patients with one or more additional non-sex specific stroke 
risk factors (i.e., a CHA2DS2-VASc score of 2). Nevertheless, OAC treatment remains in general 
under-used among AF patients with low bleeding risk and high stroke risk, and clearly warrants more 
insight and efforts among prescribing physicians.
12
 Yet, this pattern was consistent among males and 
females.
13
 
Importantly, regular clinical follow-up for the re-assessment of stroke risk factors is mandatory, since 
the risk is not static and may change over time.
9
 Indeed, the dynamic changes in stroke or bleeding risk 
profile are the best predictors of adverse outcomes.
9,10  
While it may seem appropriate to consider a 
change in the use of the CHA2DS2-VASc score to reflect that male and females have different stroke 
risk across different score levels, we do not recommend such change at this time. We fear this could 
even potentially confuse prescribing physicians, unintentionally indicating that women carry excess 
stroke risk relative to male peers.
11
 Accurate stroke risk prediction in AF is important; however, the 
prediction accuracy should be balanced against the practicality and ease of use in a busy clinical 
setting. The clinical value of refining stroke risk stratification may therefore lie in improving the 
identification of patients at sufficiently low risk of stroke. Current data suggests that female AF patients 
with no additional stroke risk factors are such candidates, and we therefore question the current US 
guideline options that include aspirin treatment or OAC treatment for these patients.
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Table 1: Contemporary guideline recommendations for initiating antithrombotic treatment in AF 
patients based on the CHA2DS2-VASc score. 
  North American guideline 
recommendations 
European guideline recommendations 
 Females Males Females Males 
CHA2DS2-VASc = 
0 
N/A* No therapy N/A* No therapy 
CHA2DS2-VASc = 
1 
OAC, aspirin, or no therapy No therapy Consider OAC 
CHA2DS2-VASc 
=2 
Recommend OAC Consider OAC Recommend OAC 
CHA2DS2-VASc ≥ 
3 
Recommend OAC 
 
*Females cannot score 0, as female sex triggers 1 point 
 
